Table 2.
Multivariable analysis of variables associated with receiving ENZ (over ABI) in ENZ-era.
| Model 1: CHEMOTHERAPY-NAÏVE (n = 1128) |
Model 2: POST-CHEMOTHERAPY (n = 263) |
|||||||
|---|---|---|---|---|---|---|---|---|
| FACTORS | OR | 95% CI | p-Value | OR | 95% CI | p-Value | ||
| Prescribing specialty (Ref: Medical oncology) | - | - | ||||||
| Urology | 1.89 | 1.38 | 2.58 | <0.001 | 3.83 | 1.76 | 8.36 | <0.001 |
| Other | 0.80 | 0.49 | 1.28 | 0.350 | 1.13 | 0.45 | 2.82 | 0.791 |
| Year of initiation (Ref: 2014) | - | - | ||||||
| 2015 | 1.57 | 1.06 | 2.33 | 0.023 | 0.93 | 0.45 | 1.94 | 0.859 |
| 2016 | 6.89 | 4.81 | 9.87 | <0.001 | 2.25 | 1.13 | 4.47 | 0.022 |
| Age (Ref: <75) | - | - | ||||||
| ≥75 | 1.38 | 1.01 | 1.88 | 0.041 | 1.54 | 0.81 | 2.90 | 0.180 |
| Residence (Ref: Urban) | - | - | ||||||
| Rural | 1.54 | 1.13 | 2.07 | 0.005 | 0.67 | 0.35 | 1.24 | 0.205 |
| Symptomatic indicator (Ref: No) | - | - | ||||||
| Yes | 0.94 | 0.70 | 1.26 | 0.688 | 0.93 | 0.52 | 1.69 | 0.834 |
| Prior Bone-targeted therapy (Ref: No) | - | - | ||||||
| Yes | 1.49 | 1.08 | 2.03 | 0.013 | 1.00 | 0.53 | 1.87 | 0.992 |
| Prior local treatment (Ref: No) | - | - | ||||||
| Yes | 0.86 | 0.64 | 1.17 | 0.341 | 0.66 | 0.35 | 1.24 | 0.201 |
| Charlson comorbidity index (Ref: <4) | - | |||||||
| ≥4 | 1.09 | 0.61 | 1.97 | 0.752 | 0.68 | 0.16 | 2.89 | 0.612 |
| Hypertension (Ref: No) | - | - | ||||||
| Yes | 0.78 | 0.55 | 1.11 | 0.169 | 1.47 | 0.73 | 2.96 | 0.269 |
| Hyperlipidemia (Ref: No) | - | |||||||
| Yes | 1.18 | 0.86 | 1.63 | 0.286 | 1.18 | 0.61 | 2.29 | 0.610 |
| Diabetes (Ref: No) | - | |||||||
| Yes | 1.30 | 0.91 | 1.84 | 0.149 | 1.13 | 0.55 | 2.31 | 0.746 |
| Cardiovascular condition (Ref: 0) | - | |||||||
| ≥1 | 1.54 | 1.06 | 2.25 | 0.022 | 0.65 | 0.32 | 1.35 | 0.257 |
Abbreviations: ABI = abiraterone acetate; CI = confidence interval; ENZ = enzalutamide; OR = odds ratio; Ref = reference.